A laboratory-acquired infection with Neisseria meningitidis

Bhatti, A. R.; DiNinno, V L; Ashton, F. E.; White, L A

doi:10.1016/s0163-4453(82)92563-4

Cited by 15 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Permanent sequelae are common among college students surviving meningococcal infection (95). There have been numerous reports of laboratory-acquired meningococcal infection, mostly among microbiologists manipulating the organism on an open laboratory bench (27,61,62,258,267).…”

Section: Risk Factors For Infectionmentioning

confidence: 99%

Prospects for Vaccine Prevention of Meningococcal Infection

2006

View full text Add to dashboard Cite

SUMMARY Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.

show abstract

Section: Risk Factors For Infectionmentioning

confidence: 99%

Prospects for Vaccine Prevention of Meningococcal Infection

2006

View full text Add to dashboard Cite

show abstract

“…Reports of cases of invasive disease caused by Neisseria meningitidis infection acquired in the laboratory setting have appeared in the literature for many years (1,3,13,(15)(16)(17)20). However, a systematic evaluation of the risk of meningococcal disease among clinical microbiologists and an assessment of the potential laboratory procedures that might predispose technicians to infection have not previously been undertaken.…”

mentioning

confidence: 99%

Assessing the Risk of Laboratory-Acquired Meningococcal Disease

et al. 2005

View full text Add to dashboard Cite

Neisseria meningitidis is infrequently reported as a laboratory-acquired infection. Prompted by two cases in the United States in 2000, we assessed this risk among laboratorians. We identified cases of meningococcal disease that were possibly acquired or suspected of being acquired in a laboratory by placing an information request on e-mail discussion groups of infectious disease, microbiology, and infection control professional organizations. A probable case of laboratory-acquired meningococcal disease was defined as illness meeting the case definition for meningococcal disease in a laboratorian who had occupational exposure to an N. meningitidis isolate of the same serogroup within 14 days of illness onset. Sixteen cases of probable laboratory-acquired meningococcal disease occurring worldwide between 1985 and 2001 were identified, including six U.S. cases between 1996 and 2000. Nine cases (56%) were serogroup B; seven (44%) were serogroup C. Eight cases (50%) were fatal. All cases occurred among clinical microbiologists. In 15 cases (94%), isolate manipulation was performed without respiratory protection. We estimated that an average of three microbiologists are exposed to the 3,000 meningococcal isolates seen in U.S. laboratories yearly and calculated an attack rate of 13/100,000 microbiologists between 1996 and 2001, compared to 0.2/100,000 among U.S. adults in general. The rate and case/fatality ratio of meningococcal disease among microbiologists are higher than those in the general U.S. population. Specific risk factors for laboratory-acquired infection are likely associated with exposure to droplets or aerosols containing N. meningitidis. Prevention should focus on the implementation of class II biological safety cabinets or additional respiratory protection during manipulation of suspected meningococcal isolates.

show abstract

“…Immunoblot analysis with MPI also displayed the epidemiological usefulness of monoclonal antibodies. This was with strain DRES 30-A which had been isolated from an individual infected while working with SP3428, SP3428-P, and SP3428-NP (1). The piliation of DRES 30-A was identical to that of SP3428, implicating this as the infecting strain rather than SP3428-P or SP3428-NP.…”

Section: Discussionmentioning

confidence: 88%

Structural and antigenic analysis of meningococcal piliation

Olafson¹,

McCarthy²,

Bhatti³

et al. 1985

Infect Immun

View full text Add to dashboard Cite

Pilin with an M, of 16,500 was purified to homogeneity from Neisseria meningitidis SP3428. Procedures which provided useful separation during purification included high-pressure liquid chromatography with a TSK size exclusion column, Sephacryl S-200 column chromatography, ion-exchange chromatography with SP-Sephadex, and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The amino acid composition of this pilin was similar to that previously reported for this species. The sequence of the N-terminal 51 amino acids was also determined. The protein lacked a modified phenylalanine at the amino terminus and displayed six residues which were different from Neisseria gonorrhoeae in that region of the molecule determined to be the lectin-binding domain. Monoclonal antibody raised to this pilin was employed, along with a monoclonal antibody to an epitope common to all gonococcal pilins, to analyze the intraand interstrain heterogeneity of meningococcal piliation. The results indicate that N. meningitidis displays considerable intraand interstrain heterogeneity with respect to both pilus subunit size and antigenicity. The Mr of subunits ranged from 13,000 to 20,000.

show abstract

A laboratory-acquired infection with Neisseria meningitidis

Cited by 15 publications

References 10 publications

Prospects for Vaccine Prevention of Meningococcal Infection

Prospects for Vaccine Prevention of Meningococcal Infection

Assessing the Risk of Laboratory-Acquired Meningococcal Disease

Structural and antigenic analysis of meningococcal piliation

Contact Info

Product

Resources

About